

Optimization of dendritic cell labeling for MR tracking after vaccination in cancer patients

P. Verdijk¹, T. W. Scheenen², A. A. Veltien², J. W. Bulte³, P. Walczak³, W. J. Lesterhuis⁴, I. J. de Vries^{1,5}, C. J. Punt⁴, A. Heerschap², C. G. Figdor¹

¹Tumor Immunology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ²Radiology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, United States, ⁴Oncology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ⁵Pediatric Oncology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands

Introduction

Dendritic cells (DCs) are the professional antigen presenting cells of the immune system. Recent clinical studies indicate that mature DCs are effective cancer vaccines when loaded with tumor antigens¹. To induce an effective immune response, these cells should not only express high levels of antigen-presenting and co-stimulatory molecules but also migrate to the lymph nodes (LN) to interact with naïve T cells. Monitoring cellular migration *in vivo* is important to improve the efficacy of DC-based therapies². Recently we demonstrated that DCs labeled with superparamagnetic iron oxide (SPIO) can be imaged and tracked in melanoma patients after intranodal injection³. Here we demonstrate in detail that DCs can be efficiently labeled with SPIO without affecting DC function and that low numbers of SPIO-labeled DC can be imaged *in vitro* on a 3T MR whole body scanner using clinically applicable parameters.

Materials and Methods

Autologous DCs were cultured from monocytes obtained from peripheral blood³ and labeled with the clinically approved SPIO formulation Endorem® by adding various amounts of SPIO to the DC culture one day before adding the maturation factors. Iron contents of DCs were determined by Prussian Blue staining and by measuring the average amount of iron per cell using a Ferrozin-based spectrophotometric iron assay⁴. The phenotype, T cell stimulatory function and migratory behavior on fibronectin-coated plates⁵ were determined of both SPIO-labeled and unlabeled DCs. MR imaging of phantoms, containing SPIO-labeled DC in 6% gelatin between to layers of 8% gelatin, was performed at 3T (Siemens Magnetom Trio), using a body phased array coil. Samples were imaged using T2*-w gradient echo (GRE; TR 800 ms, TSE 15 ms, flip angle 35°; resolution 0.5 × 0.5 × 5.5 mm³) sequences.

Results and Discussion

DCs were effectively labeled with SPIO by adding the particles to the immature DC culture one day before maturation (Fig. 1A). The iron content per cell increased in a linear fashion with increasing concentrations of SPIO in culture (Fig. 1B). As at the highest concentration of SPIO (400 µg/ml) the cell viability was decreased, 200 µg/ml of SPIO was chosen as the optimal dose. At this concentration, phenotypic characterization of DC by flowcytometry for DC maturation markers showed that SPIO did not influence DC differentiation and maturation. Furthermore, both the allogeneic and autologous T cell stimulatory capacity of DCs was not changed by the addition of SPIO. Moreover, the migratory capacity of SPIO-labeled cells was still intact (Fig. 1C). Cell densities of 100/µl could still be observed in GRE images of phantoms (Fig. 1D). Using a threshold of 50% signal decrease in a GRE image, which is appropriate for *in vivo* conditions and signal to noise, we estimate to be able to detect 10³ DCs/µl if present throughout some adjacent voxels. With a typical *in vivo* spatial resolution of 0.5 × 0.5 × 3.5 mm this means we can detect 0.9 × 10³ DCs/voxel if present in ~4 adjacent voxels. By using a local surface coil for signal reception the spatial resolution can be increased to 0.5 × 0.5 × 0.5 mm pushing the detection limit down to 0.1 × 10³ DCs/voxel in 4 voxels.




Figure 1: A. Prussian Blue staining of DCs cultured with increasing concentrations of SPIO (0-400 µg/ml). B. Average amount of iron oxide per cell for DC cultures with increasing amounts of SPIO. C. Percentage of migrating DC on fibronectin after labeling with SPIO compared to unlabeled cells. D. GRE image of phantoms containing increasing numbers of DCs cultured with 200 µg/ml (~25.5 pg/cell of iron oxide) imaged on a 3T whole body scanner. Tubes contain 10¹-10⁴ SPIO-labeled DC/µl in a volume of 100 µl.

Conclusions

DC labeling with SPIO was efficient and did not affect DC function and migration at a concentrations of 200 µg/ml in the medium. Therefore, labeling DC with SPIO particles is a clinically safe method (without the need of adjunct transfection agents) for monitoring cell migration of cell vaccines. Low densities of SPIO-labeled DC can be imaged on the 3T spectrometer, demonstrating its potential for *in vivo* tracking of SPIO-labeled cells at a therapeutic dose.

References

- Schuler G, Schuler-Thurner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. *Curr Opin Immunol* 15:138-147, 2003
- Figdor CG, de Vries IJ, Lesterhuis WJ, et al: Dendritic cell immunotherapy: mapping the way. *Nat Med* 10:475-480, 2004
- De Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, Oyen WJ, Bonenkamp JJ, Boezeman JB, Adema GJ, Bulte JW, Scheenen TW, Punt CJ, Heerschap A, Figdor CG. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. *Nat Biotechnol.* 23:1407-1413, 2005.
- Bulte JW, Douglas T, Witwer B, Zhang SC, Strable E, Lewis BK, Zywicke H, Miller B, van Gelderen P, Moskowitz BM, Duncan ID, Frank JA. Magnetodendrimers allow endosomal magnetic labeling and *in vivo* tracking of stem cells. *Nat Biotechnol.* 19:1141-1147, 2001.
- Krooshoop DJ, Torensma R, van den Bosch GJ, Nelissen JM, Figdor CG, Raymakers RA, Boezeman JB. An automated multi well cell track system to study leukocyte migration. *J Immunol Methods* 280:89-102, 2003.